HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

GLP-1 breast cancer survival study reports up to 91% lower mortality; critics cite flaws

Louis Nervegna · May 14, 2026 · ♥ 2 reactions · 0 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)CancerHow to read research
AI summary & key facts

Medscape reports a JAMA Network Open analysis of electronic health records of over 800,000 US women with breast cancer, with GLP-1 users showing substantially lower 10-year mortality and recurrence. Critics call the analysis fundamentally flawed, and the authors call for randomized trials.

#glp1HD #breastcancerHD #jamaHD

Research cited

Shared from Medscape · original post

A large real-world study is raising the possibility that GLP-1 drugs can improve long-term survival after breast cancer. But critics charge that the analysis is full of fundamental flaws.

The study, which combed electronic health records from over 800,000 US women with breast cancer, found that GLP-1 users had a substantially reduced risk of dying over 10 years — as much as 91% lower for women who used the drugs to manage diabetes than for those using other diabetes medications. The risk for breast cancer recurrence was also significantly curbed.

The researchers say their findings, published in JAMA Network Open, warrant further evaluation in randomized trials. Can GLP-1 Drugs Improve Breast Cancer Survival? (Medscape)

No photo description available.
← newer: Blood NAD+ is a useless aging biomarker: stable across sevenolder: Mendelian randomization: high VO2max is a health proxy, not →